HomeCompareABT vs SLB

ABT vs SLB: Dividend Comparison 2026

ABT yields 2.36% · SLB yields 2.23%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABT wins by $512.2K in total portfolio value
10 years
ABT
ABT
● Live price
2.36%
Share price
$101.89
Annual div
$2.40
5Y div CAGR
63.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$533.6K
Annual income
$328,772.04
Full ABT calculator →
SLB
SLB
● Live price
2.23%
Share price
$51.53
Annual div
$1.15
5Y div CAGR
-12.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$62.32
Full SLB calculator →

Portfolio growth — ABT vs SLB

📍 ABT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABTSLB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABT + SLB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABT pays
SLB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABT
Annual income on $10K today (after 15% tax)
$200.23/yr
After 10yr DRIP, annual income (after tax)
$279,456.23/yr
SLB
Annual income on $10K today (after 15% tax)
$189.70/yr
After 10yr DRIP, annual income (after tax)
$52.97/yr
At 15% tax rate, ABT beats the other by $279,403.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABT + SLB for your $10,000?

ABT: 50%SLB: 50%
100% SLB50/50100% ABT
Portfolio after 10yr
$277.5K
Annual income
$164,417.18/yr
Blended yield
59.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SLB right now

ABT
Analyst Ratings
30
Buy
10
Hold
Consensus: Buy
Price Target
$137.67
+35.1% upside vs current
Range: $120.00 — $158.00
Altman Z
4.9
Piotroski
6/9
SLB
Analyst Ratings
56
Buy
6
Hold
4
Sell
Consensus: Buy
Price Target
$52.95
+2.8% upside vs current
Range: $45.00 — $61.00
Altman Z
3.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABT buys
0
SLB buys
0
No recent congressional trades found for ABT or SLB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABTSLB
Forward yield2.36%2.23%
Annual dividend / share$2.40$1.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR63.2%-12.7%
Portfolio after 10y$533.6K$21.4K
Annual income after 10y$328,772.04$62.32
Total dividends collected$492.4K$1.2K
Payment frequencyquarterlyquarterly
SectorHealthcareEnergy
Analyst consensusBuyBuy
Analyst price target$137.67$52.95

Year-by-year: ABT vs SLB ($10,000, DRIP)

YearABT PortfolioABT Income/yrSLB PortfolioSLB Income/yrGap
1← crossover$11,084$384.43$10,895$194.83+$189.00ABT
2$12,510$649.94$11,831$173.18+$679.00ABT
3$14,505$1,118.82$12,812$153.43+$1.7KABT
4$17,499$1,978.53$13,845$135.57+$3.7KABT
5$22,364$3,640.59$14,933$119.52+$7.4KABT
6$31,026$7,096.70$16,084$105.19+$14.9KABT
7$48,215$15,016.56$17,302$92.43+$30.9KABT
8$87,182$35,592.30$18,594$81.13+$68.6KABT
9$191,446$98,161.15$19,967$71.13+$171.5KABT
10$533,619$328,772.04$21,427$62.32+$512.2KABT

ABT vs SLB: Complete Analysis 2026

ABTHealthcare

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Full ABT Calculator →

SLBEnergy

SLB N.V. engages in the provision of technology for the energy industry worldwide. The company operates through four divisions: Digital & Integration, Reservoir Performance, Well Construction, and Production Systems. The company provides field development and hydrocarbon production, carbon management, and integration of adjacent energy systems; reservoir interpretation and data processing services for exploration data; and well construction and production improvement services and products. It also offers subsurface geology and fluids evaluation information; stimulation services to restore or enhance well productivity through hydraulic fracturing, matrix stimulation, and water treatment; and intervention services to oil and gas operators. In addition, the company offers mud logging, directional drilling, measurement-while-drilling, and logging-while-drilling services, as well as engineering support services; supplies drilling fluid systems; designs, manufactures, and markets roller cone and fixed cutter drill bits; bottom-hole-assembly and borehole enlargement technologies; well planning, well drilling, engineering, supervision, logistics, procurement, and contracting of third parties, as well as drilling rig management solutions; and drilling equipment and services, as well as land drilling rigs and related services. Further, it provides artificial lift; supplies packers, safety valves, sand control technology, and various intelligent systems; midstream production systems; valves, chokes, actuators, and surface trees; and OneSubsea, an integrated solutions, products, systems, and services, including wellheads, subsea trees, manifolds and flowline connectors, control systems, connectors, and services. The company was formerly known as Schlumberger Limited and change its name to SLB N.V. in October 2025. SLB N.V. was founded in 1926 and is based in Houston, Texas.

Full SLB Calculator →
📬

Get this ABT vs SLB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABT vs SCHDABT vs JEPIABT vs OABT vs KOABT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.